Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Thoracic Cancer|December 19, 2017
Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinomaYou-Cai Zhu, Xing-Hui Liao, Wen-Xian Wang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|November 16, 2018
Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)Quxia Zhang, Chunwei Xu, Wenxian Wang, et al.
Cancer Biology & Therapy|August 11, 2018
A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinibYou-Cai Zhu, Wen-Xian Wang, Chun-Wei Xu, et al.
Oncotarget|November 16, 2017
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancerGen Lin, Xirong Fan, Weifeng Zhu, et al.
Translational Cancer Research|February 4, 2022
Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinibYou-Cai Zhu, Bing Wan, Li-Xin Wu, et al.
International Journal of Clinical and Experimental Pathology|January 23, 2020
Genetic mutations in lung enteric adenocarcinoma identified using next-generation sequencingLi Lin, Wu Zhuang, Wenxian Wang, et al.
Scientific Reports|October 4, 2024
Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial resultYaping Hong, Wu Zhuang, Jinhuo Lai, et al.
Frontiers in Oncology|November 9, 2020
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung CancerWenxian Wang, Zhangzhou Huang, Zongyang Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2023
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)Yuanyuan Zhao, Yuxiang Ma, Yun Fan, et al.
Oncotargets and Therapy|July 20, 2017
Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case reportYou-Cai Zhu, Xing-Hui Liao, Wen-Xian Wang, et al.
Pageof 10